559 related articles for article (PubMed ID: 29079134)
1. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
2. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review.
Ganguly BB; Dolai TK; De R; Kadam NN
J Cancer Res Ther; 2016; 12(3):1203-1206. PubMed ID: 28054536
[TBL] [Abstract][Full Text] [Related]
4. [Research Progress on Gene Mutation and CHIP in Pathogenesis of MDS --Review].
He M; Wu T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):907-910. PubMed ID: 37356959
[TBL] [Abstract][Full Text] [Related]
5. Genetics of MDS.
Ogawa S
Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
[TBL] [Abstract][Full Text] [Related]
6. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
7. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
Tang G; Medeiros LJ; Wang SA
Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
[TBL] [Abstract][Full Text] [Related]
8. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
9. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
10. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
11. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
12. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE; Malcovati L; Ebert BL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
[TBL] [Abstract][Full Text] [Related]
13. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
Harada H
Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathogenesis of MDS.
Look AT
Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
[TBL] [Abstract][Full Text] [Related]
15. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
Panani AD; Roussos C
Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
[TBL] [Abstract][Full Text] [Related]
18. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
[TBL] [Abstract][Full Text] [Related]
19. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
Sperling AS; Gibson CJ; Ebert BL
Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA; Ebert BL
J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
